Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Comparison of gemcitabine plus platinum analog with gemcitabine alone in advanced pancreatic cancer

Nature Clinical Practice Oncology volume 5, pages 312–313 (2008)Cite this article

Heinemann V et al. (2007) Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study. Ann Oncol 18: 1652–1659

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Moore MJ et al. (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: 1960–1966

    Article  CAS  Google Scholar 

  2. Sultana A et al. (2007) Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 25: 2607–2615

    Article  Google Scholar 

  3. Poplin E et al. (2006) Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion [FDR]) versus gemcitabine plus oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201) [summary]. J Clin Oncol 24: s180

    Google Scholar 

  4. Kindler HL et al. (2007) A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis of Cancer and Leukemia Group B (CALGB) [abstract]. J Clin Oncol 25

  5. Philip PA et al. (2007) Phase III study of gemcitabine (G) plus cetuximab (C) versus gemcitabine in patients (pts) with locally advanced or metastatic pancreatic adenocarcinoma (PC): SWOG S0205 study [abstract]. J Clin Oncol 25

Download references

Acknowledgements

The synopsis was written by Mandy Aujla, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. EM O'Reilly is an Associate Member, and GK Abou-Alfa is an Assistant Member, at Memorial Sloan–Kettering Cancer Center, and EM O'Reilly is an Associate Professor of Medicine, and GK Abou-Alfa is an Assistant Professor of Medicine, at Weill Cornell Medical University, New York, NY, USA.,

    Eileen M O'Reilly & Ghassan K Abou-Alfa

Authors
  1. Eileen M O'Reilly
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ghassan K Abou-Alfa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eileen M O'Reilly.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

O'Reilly, E., Abou-Alfa, G. Comparison of gemcitabine plus platinum analog with gemcitabine alone in advanced pancreatic cancer. Nat Rev Clin Oncol 5, 312–313 (2008). https://doi.org/10.1038/ncponc1128

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc1128

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing